-
This online marketplace stock has been added to Citi's value creators focus list
-
Citi makes changes to its SMID value creators list
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
Karuna Therapeutics Inc. (KRTX) Surges After Trial Meets Primary Endpoint
-
Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference
-
UPDATE: Citi Starts Karuna Therapeutics Inc. (KRTX) at Buy
-
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
Karuna Therapeutics Inc. (KRTX) Prices 2.6M Share Offering at $96/Sh
-
Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
-
Karuna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock
-
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
-
Karuna Therapeutics Inc. (KRTX) PT Raised to $115 at Citi
-
Karuna Therapeutics to Present at Upcoming Investor Conferences
-
Citi Starts Karuna Therapeutics Inc. (KRTX) at Buy
-
Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Karuna Therapeutics, Inc. (KRTX) Prices 5.578M Share Upsized IPO at $16/Sh
-
Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering